

1 Pazufloxacin Mesilate Injection

2 パズフロキサシンメシル酸塩注射液

3

4 Pazufloxacin Mesilate Injection is an aqueous injection.

5 It contains not less than 95.0% and not more than 105.0%
6 of the labeled amount of pazufloxacin mesilate
7 ($C_{16}H_{15}FN_2O_4 \cdot CH_4O_3S$: 414.41).

8 **Method of preparation** Prepare as directed under Injections,
9 with Pazufloxacin Mesilate.

10 **Description** Pazufloxacin Mesilate Injection is a clear, colorless
11 liquid.

12 **Identification** To a volume of Pazufloxacin Mesilate Injection,
13 equivalent to 20 mg of Pazufloxacin Mesilate, add a mixture of
14 methanol and 1 mol/L hydrochloric acid VS (49:1) to make 100
15 mL. To 5 mL of this solution add a mixture of methanol and 1
16 mol/L hydrochloric acid VS (49:1) to make 100 mL. Determine
17 the absorption spectrum of this solution as directed under Ultravi-
18 olet-visible Spectrophotometry <2.24>: it exhibits maxima be-
19 tween 237 nm and 241 nm, between 314 nm and 324 nm, between
20 328 nm and 332 nm, and between 343 nm and 347 nm.

21 **pH** Being specified separately when the drug is granted ap-
22 proval based on the Law.

23 **Bacterial endotoxins** <4.01> Less than 0.3 EU/mg.

24 **Extractable volume** <6.05> It meets the requirement.

25 **Foreign insoluble matter** <6.06> Perform the test according to
26 Method 1: it meets the requirement.

27 **Insoluble particulate matter** <6.07> It meets the requirement.

28 **Sterility** <4.06> Perform the test according to the Membrane fil-
29 tration method: it meets the requirement.

30 **Assay** Pipet a volume of Pazufloxacin Mesilate Injection, equiv-
31 alent to about 12 mg of pazufloxacin mesilate
32 ($C_{16}H_{15}FN_2O_4 \cdot CH_4O_3S$), and add water to make exactly 50 mL.
33 Pipet 5 mL of this solution, add exactly 5 mL of the internal stand-
34 ard solution, and use this solution as the sample solution. Sepa-
35 rately, weigh accurately about 23 mg of Pazufloxacin Mesilate RS,
36 previously dried at 105°C for 3 hours, and add water to make ex-
37 actly 100 mL. Pipet 5 mL of this solution, add exactly 5 mL of the
38 internal standard solution, and use this solution as the standard so-
39 lution. Perform the test with 10 μ L each of the sample solution and
40 standard solution as directed under Liquid Chromatography
41 <2.01> according to the following conditions, and calculate the ra-
42 tios, Q_T and Q_S of the peak area of pazufloxacin to that of the in-
43 ternal standard.

44 Amount (mg) of pazufloxacin mesilate ($C_{16}H_{15}FN_2O_4 \cdot CH_4O_3S$)
45 $= M_S \times Q_T / Q_S \times 1/2$

46 M_S : Amount (mg) of Pazufloxacin Mesilate RS taken

47 **Internal standard solution**— A solution of acetanilide in the mo-
48 bile phase (3 in 10,000).

49 **Operating conditions**—

50 Proceed as directed in the operating conditions in the Assay
51 under Pazufloxacin Mesilate.

52 **System Suitability**—

53 System performance: When the procedure is run with 10 μ L of
54 the standard solution under the above operating conditions,
55 pazufloxacin and acetanilide are eluted in this order with the
56 resolution between these peaks being not less than 3.

57 System repeatability: When the test is repeated 6 times with 10
58 μ L of the standard solution under the above operating conditions,
59 the relative standard deviation of the ratio of the peak area of
60 pazufloxacin to that of the internal standard is not more than 1.0%.

61 **Containers and storage** Containers — Hermetic containers.
62 Plastic containers for aqueous injections may be used.

63 Storage — Light-resistant.

64 **Add the following to 9.01 Reference Stand-**
65 **ards (1):**

66 Pazufloxacin Mesilate RS

67